Severe pancytopenia after leflunomide in rheumatoid arthritis

被引：20

作者：

Auer, J ^{[1
]}

Hinterreiter, M ^{[1
]}

Allinger, S ^{[1
]}

Kirchgatterer, A ^{[1
]}

Knoflach, P ^{[1
]}

机构：

[1] Gen Hosp, Med Dept Gastroenterol & Rheumatol 1, A-4600 Wels, Austria

来源：

ACTA MEDICA AUSTRIACA | 2000年 / 27卷 / 04期

关键词：

leflunomide; bone marrow toxicity; pancytopenia; rheumatoid arthritis;

D O I：

10.1046/j.1563-2571.2000.00034.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Leflunomide is a novel drug recently introduced for treatment of rheumatoid arthritis as a DMARD (disease-modifying antirheumatic drug). So far, leflunomide has not been associated with severe bone marrow toxicity and pancytopenia. We report of a 62-year-old woman with a 14-year history of rheumatoid arthritis with bone marrow toxicity and reversible pancytopenia developing after treatment with leflunomide.

引用

页码：131 / 132

页数：2

共 4 条

[1]

Elder RT, 1997, J IMMUNOL, V159, P22

[2]

Fox RI, 1998, J RHEUMATOL, V25, P20

[3] SAFETY AND EFFECTIVENESS OF LEFLUNOMIDE IN THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID-ARTHRITIS - RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, PHASE-II STUDY [J].

MLADENOVIC, V ;

DOMLJAN, Z ;

ROZMAN, B ;

JAJIC, I ;

MIHAJLOVIC, D ;

DORDEVIC, J ;

POPOVIC, M ;

DIMITRIJEVIC, M ;

ZIVKOVIC, M ;

CAMPION, G ;

MUSIKIC, P ;

LOWFRIEDRICH, I ;

OED, C ;

SEIFERT, H ;

STRAND, V .

ARTHRITIS AND RHEUMATISM, 1995, 38 (11) :1595-1603

[4] Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial [J].

Smolen, JS ;

Kalden, JR ;

Scott, DL ;

Rozman, B ;

Kvien, TK ;

Larsen, A ;

Loew-Friedrich, I ;

Oed, C ;

Rosenburg, R .

LANCET, 1999, 353 (9149) :259-266

← 1 →